Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
11 05 2023
11 05 2023
Historique:
received:
30
11
2022
accepted:
04
05
2023
medline:
15
5
2023
pubmed:
12
5
2023
entrez:
11
5
2023
Statut:
epublish
Résumé
Low grade serous ovarian carcinoma (LGSOC) demonstrates unique clinical and molecular features compared to other ovarian cancer types. The relationship between common histological features of LGSOC and molecular events, such as hormone receptor expression patterns and MAPK gene mutation status, remains poorly understood. Recent data suggest some of these molecular features may be biomarkers of response to recently introduced biologically-targeted therapies, namely endocrine therapy and MEK inhibitors. We utilize a cohort of 63 pathologically-confirmed LGSOC cases with whole exome sequencing and hormone receptor expression data to investigate these relationships. LGSOC cases demonstrated uniformly high oestrogen receptor (ER) expression, but variable progesterone receptor (PR) expression intensity. 60% and 37% of cases demonstrated micropapillary and macropapillary patterns of stromal invasion, respectively. 63% of cases demonstrated desmoplasia, which was significantly associated with advanced disease stage and visible residual disease after cytoreductive surgery. MAPK-mutant cases (KRAS, BRAF, NRAS) more frequently demonstrated macropapillary stromal invasion, while Chr1p loss was associated with desmoplasia and low PR expression. Presence of micropapillary stromal invasion and low PR expression were associated with significantly poorer survival after accounting for stage and residual disease status. Together, these data identify novel relationships between histopathological features and molecularly-defined subgroups in LGSOC.
Identifiants
pubmed: 37169775
doi: 10.1038/s41598-023-34627-5
pii: 10.1038/s41598-023-34627-5
pmc: PMC10175560
doi:
Substances chimiques
Receptors, Estrogen
0
Hormones
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7681Subventions
Organisme : Cancer Research UK
Pays : United Kingdom
Informations de copyright
© 2023. The Author(s).
Références
Am J Clin Pathol. 2004 Jun;121(6):857-66
pubmed: 15198358
Gynecol Oncol. 2012 Aug;126(2):279-85
pubmed: 22555104
Gynecol Oncol. 2020 Mar;156(3):715-725
pubmed: 31969252
Histopathology. 2006 Jun;48(7):787-94
pubmed: 16722926
Cancer Res. 2021 Apr 1;81(7):1681-1694
pubmed: 33441310
Gynecol Oncol. 2017 Oct;147(1):85-91
pubmed: 28768570
Gynecol Oncol. 2008 Mar;108(3):510-4
pubmed: 18155273
Gynecol Oncol. 2022 Jun;165(3):560-567
pubmed: 35606067
Am J Surg Pathol. 2008 Dec;32(12):1800-6
pubmed: 18779727
Cancers (Basel). 2021 Nov 21;13(22):
pubmed: 34830992
Gynecol Oncol. 2012 Jun;125(3):661-6
pubmed: 22406638
Lancet Oncol. 2013 Aug;14(9):853-62
pubmed: 23845225
Clin Cancer Res. 2022 Oct 14;28(20):4456-4465
pubmed: 35443055
Gynecol Oncol. 2019 Sep;154(3):531-538
pubmed: 31227223
Mol Cancer Ther. 2022 Dec 2;21(12):1862-1874
pubmed: 36198031
Sci Rep. 2020 Nov 17;10(1):20012
pubmed: 33203969
J Minim Invasive Gynecol. 2022 Sep;29(9):1083-1091
pubmed: 35649479
Am J Surg Pathol. 2004 Apr;28(4):496-504
pubmed: 15087669
Genome Biol. 2015 Feb 27;16:49
pubmed: 25887352
J Pathol. 2021 Jan;253(1):41-54
pubmed: 32901952
Am J Surg Pathol. 2019 Jun;43(6):802-809
pubmed: 30864975
Clin Cancer Res. 2002 Jul;8(7):2233-9
pubmed: 12114425
J Pathol. 2012 Feb;226(3):413-20
pubmed: 22102435
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
J Clin Oncol. 2020 Nov 10;38(32):3753-3762
pubmed: 32822286
Cochrane Database Syst Rev. 2022 Sep 26;9:CD015048
pubmed: 36161421
Am J Surg Pathol. 1994 Dec;18(12):1224-32
pubmed: 7977945
Nat Rev Cancer. 2015 Nov;15(11):668-79
pubmed: 26493647
Gynecol Oncol. 2022 Oct 10;:
pubmed: 36229265
Lancet Oncol. 2021 Feb;22(2):277-288
pubmed: 33357510
Gynecol Oncol. 2016 Mar;140(3):457-62
pubmed: 26807488
Nat Genet. 2018 Sep;50(9):1262-1270
pubmed: 30104763
Diagnostics (Basel). 2022 Feb 10;12(2):
pubmed: 35204549
NPJ Precis Oncol. 2021 Jun 2;5(1):47
pubmed: 34079052
Lancet. 2022 Feb 5;399(10324):541-553
pubmed: 35123694
J Natl Cancer Inst. 2019 Jan 1;111(1):60-68
pubmed: 29718305
BJOG. 2020 Oct;127(11):1409-1420
pubmed: 32285600
Br J Cancer. 2022 Oct;127(6):1034-1042
pubmed: 35715633
Gynecol Oncol. 2019 Nov;155(2):318-323
pubmed: 31495455
Mod Pathol. 2008 Aug;21(8):992-1001
pubmed: 18516041
Gynecol Oncol. 2019 Feb;152(2):278-285
pubmed: 30501904
J Clin Oncol. 2017 Apr 1;35(10):1103-1111
pubmed: 28221866
Cancer Lett. 2023 Feb 28;555:216057
pubmed: 36627048
Cancer Res. 2017 Aug 15;77(16):4268-4278
pubmed: 28646021
Gynecol Obstet Invest. 2022;87(3-4):242-247
pubmed: 35584619
Am J Surg Pathol. 2016 May;40(5):627-35
pubmed: 26900814
J Natl Compr Canc Netw. 2022 Sep;20(9):972-980
pubmed: 36075393
Oncotarget. 2015 Nov 10;6(35):37663-77
pubmed: 26506417
Gynecol Oncol. 2020 Apr;157(1):12-20
pubmed: 31954537
Clin Cancer Res. 2015 Aug 1;21(15):3561-8
pubmed: 25695692